Its an inter-professional and collaborative learning platform for the doctors and other healthcare professionals to discuss on various healthcare issues and views with pharmacy professionals. Pharmacist also can assist and share your ideas for the better therapeutic outcomes based on clear evidence. E.g: Drug Information, Decision Analysis and EBM.
Forum rules: The contents of the pharmdinfo.com, such as text, graphics, images, and other material contained on the pharmdinfo.com Site ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Pharmdinfo.com Site!
If you think you may have a medical emergency, call your doctor or 108 immediately. pharmdinfo.com does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Site
US regulators have green-lighted the use of Impax’ Zomig to treat migraine in patients aged 12 years and older, marking approval of the first nasally-delivered prescription medicine for this age group. The US Food Administration’s nod is for the treatment of acute migraine with or without aura, offering an alternative method of delivery that is particularly useful for those who experience related nausea or are unable to take an oral formulation. Zomig (zolmitriptan) Nasal Spray was first approved in the US for adults with acute migraine in September 2003. Paediatric clearance is based on clinical data showing that the spray is significantly more effective in addressing symptoms of migraine than a placebo, with a similar safety profile to that seen in adults, the firm said. The one-year prevalence of migraine among US children aged 12 to 19 is estimated by the American Migraine Prevalence and Prevention Study to be around 6.3%, and treatment options for this age group remain limited.